Mastering MedTech

Most founders think marketing can wait until they have a working prototype or need to raise money. By the time you need a pitch deck or professional website, it's already too late to do them well. Whit Slightham knows this from both sides. She's led communications for a multi-billion dollar biomedical research institute, founded Mesa Marketing to work with medtech startups, and she's currently living the founder journey herself. Her company Ateleva is developing a minimally invasive balloon catheter for treating lobar collapse in ICU patients. In this episode, Whit breaks down why checking trademark availability matters before you build brand equity, how to build a pitch deck that earns investor time in the first two minutes, and why you need three versions of your deck for different audiences. She also shares her own founder journey from April idea to filed patents and pitch competition wins, what it's like being on the other side pitching her own company, and why understanding your why is the only thing that gets you through the 3000-item to-do list. If you think you'll worry about branding once you're ready to raise money, this conversation will change your timeline.

Timestamps:

00:05 - Introduction: Why marketing gets pushed to the bottom but shouldn't

02:05 - Starting with discovery: Who uses it, who approves it, who pays for it

03:30 - The trademark mistake most founders make before building brand equity

05:17 - Company names, DBAs, and brand kits: Why it matters early

07:26 - When founders wait too long: Reacting instead of leading the conversation

09:19 - Making your website look established without pretending to be 200 people

10:57 - Three marketing assets you need with no revenue: Brand kit, website, LinkedIn

13:37 - Why pitch decks take two and a half months when you think it'll be an hour

16:47 - You only get two minutes: How that reality shapes deck structure

18:45 - Three versions of your deck: Live presentations, leave behinds, appendix

22:11 - For the technical founder staring at blank slides: Start with a Word doc

23:23 - Ateleva's origin story: From April idea to filed patents in months

27:02 - Being on the other side: What it's like pitching your own company

28:59 - Peeling the onion: Every answer raises three new questions

30:34 - Regulatory pathways and de-risking as fast as possible

32:00 - If you knew what was ahead, would you still start?

35:33 - Rapid fire: Marketing assets, biggest mistakes, next two years

Follow Melita and Whit:

Connect with Melita: 

LinkedIn: https://www.linkedin.com/in/melitaball/

Website: https://www.mbcaconsulting.com/about-us

Connect with Whit: 

LinkedIn: https://www.linkedin.com/in/whitneyslightham/

Website: https://mesamarketing.io/whitney-slightham/

There are precisely two things that will sink a medtech company: finance and regulatory. Get either one wrong and you're done. Steve Duddy has spent decades in the CEO chair learning this lesson the hard way. In this episode, Steve shares why regulatory strategy must start on day one, what happens when founders try to outsmart the FDA, and why the best regulatory teams are the ones who will tell a CEO no. You'll learn about breakthrough designation and why the bar isn't as high as most founders think, how to salvage a failed pre-submission meeting, and why talking to your board members individually before board meetings prevents disaster. Steve also breaks down the difference between clearance and approval, explains why fast and right are two different things, and shares his perspective on AI in medtech and where the FDA is headed. If you think regulatory strategy can wait until you have a working prototype, this conversation will change your timeline entirely.

Timestamps:

00:04 - Introduction: Why regulatory is as critical as finance 02:00 - The costly mistake of pushing ahead without regulatory strategy

05:08 - Building FDA reputation: Why first impressions matter forever

07:32 - Coming to the regulatory table too late: A cautionary example

09:32 - Understanding the three main FDA pathways: 510(k), PMA, De Novo

12:40 - Breakthrough designation: Lower bar than most founders think

16:00 - Running pre-submissions in parallel with breakthrough applications

16:40 - What goes wrong when founders do pre-subs alone

19:48 - The language trap: Why words matter more than you think

22:28 - Predicate stacking: Taking bites of the elephant instead of swallowing it whole

23:32 - FDA uncertainty: What founders should know right now

26:00 - Compliance vs regulatory: Understanding the difference

29:00 - Quality systems and strategic acquisitions: Why strategics care now

31:40 - What makes a top-notch regulatory team

35:24 - Fast vs right: Maintaining regulatory integrity under pressure

38:12 - Board management: The one-off conversation strategy

39:36 - Commercialization: Why salespeople will make up their own words

44:40 - AI in medtech: Flying the plane while building it

47:56 - Rapid fire: First 90 days, biggest mistakes, FDA predictions

Follow Melita and Steve:

Connect with Melita: 

LinkedIn: https://www.linkedin.com/in/melitaball/

Website: https://www.linkedin.com/in/melitaball/

Connect with Steve: 

LinkedIn: https://www.linkedin.com/in/steveduddy

Website: https://duddyexecutiveservices.com/

FDA clearance used to feel like the finish line. Robert Hamilton thought so too when he founded NeuraSignal. Then he learned the hard way that regulatory approval is just the beginning. In this episode, Robert shares the journey from developing the world's first fully automated robotic system for cerebral blood flow monitoring to building a commercially successful medtech company with operations in both the US and Canada. You'll hear about the pivot from traumatic brain injury to ischemic stroke when reimbursement pathways didn't align, why expanding internationally too early cost hundreds of thousands of dollars, and how clinical trial site selection can make or break your timeline and budget. Robert breaks down the three-legged stool every founder needs (regulatory, clinical, reimbursement), why usability testing is not a checkbox exercise, and how quality management systems evolve from compliance tools into competitive advantages. If you think getting through the FDA is the hard part, this conversation will recalibrate your expectations and strategy.

Timestamps:

00:00 - Introduction: From UCLA ICU to commercializing breakthrough technology

03:00 - The accidental discovery that became Neuros Signal

05:00 - The three-legged stool: Regulatory, clinical, and reimbursement strategy

08:00 - Three company name changes: Lessons in trademarks and branding

10:00 - Why cerebral blood flow monitoring matters and the gap in the market

13:00 - Three times higher diagnostic rates: Real clinical impact stories

16:00 - When FDA clearance felt like the end (but was actually the beginning)

19:00 - Usability testing beyond regulatory checkboxes

22:00 - Fundraising realities: Structure matters as much as valuation

25:00 - The strategic approach to multiple 510(k) submissions

28:00 - Quality management systems: From compliance burden to competitive advantage

33:00 - Most expensive mistakes: International expansion and clinical trial site selection

36:00 - Why reimbursement work takes most of your time post-clearance

39:00 - Rapid fire: Post-FDA advice, regulatory strategy mistakes, resources

Follow Melita and Robert:

Connect with Melita: 

LinkedIn: https://www.linkedin.com/in/melitaball/

Website: https://www.mbcaconsulting.com/

Connect with Robert: 

LinkedIn: https://www.linkedin.com/in/hamiltonrobert/

Website: https://neurasignal.com/

Getting FDA clearance used to be the finish line. Now it's just the starting gate. Cindy Grabowski has watched medtech acquisition timelines stretch from three years to eight-plus years across her 30-year career, and she knows exactly why the rules changed. In this episode, she breaks down the 2012 turning point when big medtech companies shifted their acquisition criteria from regulatory approval to predictable payment. You'll learn why reimbursement strategy must start on day one, how to design clinical trials that work globally, and what the five-publication requirement really means for Category 1 CPT codes. If you're a founder who thinks regulatory approval will get you acquired, this conversation will change your strategy.

Timestamps:

00:00 - Introduction: The evolution of medtech acquisitions

02:00 - The 2004 shift: When big medtech changed their acquisition model

05:00 - The 2012 turning point: Predictable payment becomes the new bar

08:00 - Why FDA clearance is no longer the finish line

11:00 - Designing clinical studies with global data in mind

16:00 - How AI can accelerate protocol development

19:00 - AMA requirements for reimbursement and the five-publication rule

24:00 - The trap of "we only need enough data for regulatory approval"

29:00 - Four critical roles every founder must align from day one

33:00 - Mind Grove: Building cross-functional training for medtech professionals

36:00 - Rapid fire questions

40:00 - Where to connect with Cindy

Follow Melita and Cindy:

Connect with Melita: 

LinkedIn: https://www.linkedin.com/in/melitaball/

Website: https://www.mbcaconsulting.com/

Connect with Cindy: 

LinkedIn: https://www.linkedin.com/in/cindy-grabowski/

Website: https://mindgrove.com/

Most technical founders spend years perfecting their device, only to discover there's no market willing to pay for it. Anita Bell has seen this pattern repeat hundreds of times in her 20+ years as Director of the University of Arizona Center for Innovation. 

In this episode, Anita shares the harsh realities technical founders face when they fall in love with their technology instead of their customers. From the handheld pump that was too big for nurses' hands (discovered only after FDA approval) to the critical differences between pitching for prizes versus real investor money, Anita reveals the systematic approach her incubator uses to help founders avoid expensive mistakes. She introduces UACI's 28-point roadmap that takes companies from idea to exit, explains why "I built it and they will come" thinking kills startups, and shares why the most expensive mistake has nothing to do with technology at all.

Timestamps: 

[00:00] Welcome and Anita's journey into incubation 

[02:00] What makes startups succeed or fail 

[03:25] The 28-point roadmap approach 

[07:00] Technical founders versus business founders 

[08:15] Why customer discovery is critical 

[11:25] The handheld pump story: missing the obvious 

[14:05] Guiding founders through customer discovery 

[18:25] The "day in the life" methodology 

[22:20] Pitching for prizes versus real investors 

[28:20] Key elements of compelling MedTech pitches 

[32:40] Building support networks without formal incubators 

[36:45] International soft landing programs 

[40:05] Rapid fire: advice, resources, and predictions

Follow Melita and Anita:

Connect with Melita: 

LinkedIn: https://www.linkedin.com/in/melitaball

Website: https://www.mbcaconsulting.com/about-us

Connect with Anita: 

LinkedIn: https://www.linkedin.com/in/bellanita/

Great technology is not enough. Marco Flavio Marinucci has spent 20 years watching brilliant medtech products fail because founders didn't understand the healthcare ecosystem they were entering. In this episode, Marco breaks down why you need three different sales stories for three different stakeholders, why 40% of Americans reading at a sixth-grade level matters for your product design, and how the collapse of UX investment across tech is creating both challenges and opportunities for medtech startups. You'll learn why hospital administrators care about completely different metrics than physicians, how to test product-market fit on a limited budget using AI personas, and why spending two weeks shadowing clinicians is worth more than hiring three consultants. If you're building a device without understanding the continuum of care it fits into, this conversation will change your entire approach.

Timestamps:

00:00 - Introduction: The intersection of ethics, healthcare, and technology

05:00 - Why UX has been deprioritized and what it means for medtech startups

08:00 - The 40% literacy reality: Designing for actual users, not ideal ones

14:00 - Why large companies can get away with poor usability but you cannot

17:00 - WCAG guidelines: The accessibility requirements you cannot ignore

22:00 - The three-story sales challenge: Different stakeholders, different needs

29:00 - Hospital versus community clinic: Understanding profit margins and priorities

37:00 - The RACI matrix: Who really makes purchasing decisions in healthcare

42:00 - Why a 12-18 month sales cycle is optimistic (plan for 24)

45:00 - Warning signs your company is not prepared for healthcare sales

49:00 - Rapid fire: Testing product-market fit, using AI for user research

53:00 - If Marco started a medtech company tomorrow: First priorities

Follow Melita and Marco:

Connect with Melita: 

LinkedIn: https://www.linkedin.com/in/melitaball/

Website: https://www.mbcaconsulting.com/

Connect with Marco: 

LinkedIn: https://www.linkedin.com/in/marcoflavio/

Website: https://www.marcoflavio.work/

Seventy-one percent turnover. Production excursions every 89 days. Low engagement across the board. Graydon Hansen walked into Abbott's largest medical device plant in China facing these challenges and turned it into a top performer over five and a half years. In this episode, Graydon shares the two pillars of operational turnaround: getting your hands into everything and changing the way your people think. You'll learn why leaders who stay off the shop floor miss critical insights, how converting from paper to electronic batch records transforms quality management, and why the biggest operational mistake startups make is not looking forward to where they want to be in five years. Graydon also breaks down the three A's of AI implementation (available, actionable, accurate data), why AI skepticism comes from limited understanding rather than real risk, and how to convince conservative quality teams that AI will help them work more effectively. If you think compliance and operational efficiency are competing priorities, this conversation will change your perspective entirely.

Timestamps:

00:00 - Introduction: From commercial fishing to running Abbott's China plant

03:00 - Why the troubled China plant attracted Graydon and what made it worth taking on

04:00 - Two pillars of operational turnaround: Hands-on leadership and changing mindsets

06:00 - The shop floor strategy: Why leaders must be visible every day

08:00 - Learning from Japan's discriminating consumer and fixing supplier quality

09:00 - Scaling operations: The five whys and asking why you can't add another shift

11:00 - What a 25-year-old startup looks like operationally (and why it's common)

13:00 - Converting paper systems to electronic while maintaining product quality

16:00 - Why compliance and operational success are the same thing, not competing priorities

18:00 - Three common misconceptions about AI in medtech

20:00 - The three A's: Available, actionable, accurate data for AI implementation

22:00 - Convincing conservative quality teams that AI helps them, not threatens them

26:00 - Handling marketplace skepticism about AI in medtech

29:00 - Why Google Drive is not the answer for quality management systems

32:00 - When startups should invest in digital systems (hint: from the very beginning)

34:00 - Rapid fire: Operational excellence advice, scaling resources, biggest mistakes

Follow Melita and Graydon:

Connect with Melita: 

LinkedIn: https://www.linkedin.com/in/melitaball/

Website: https://www.mbcaconsulting.com/

Connect with Graydon: 

LinkedIn: https://www.linkedin.com/in/graydonhansen/

Website: https://www.medtechoperationsstrategiesandsolutions.com/

Most medtech founders want to skip straight to building their product. Veronica Kingston has spent 30 years watching that approach lead to expensive recalls, failed regulatory submissions, and collapsed acquisition deals. As Senior Director of Quality Management Systems and Design Quality Assurance at Thermo Fisher Scientific, she's worked with startups, navigated mergers and acquisitions, and remediated global compliance disasters.

 In this episode, Veronica breaks down the biggest misconception about design controls (that you can retrofit them later), explains why the most expensive mistake startups make is ignoring the framework upfront, and reveals the three compliance issues that consistently require remediation. She shares practical advice on when to bring in quality and regulatory expertise, how to build teams that can navigate gray areas, and what to do when you're facing your first FDA 483. 

Timestamps:

• [00:00:00] Introduction to Veronica Kingston's 30-year quality career

• [00:03:10] The biggest differences between small and large company quality approaches

• [00:05:10] What design controls really are and why they matter

• [00:09:10] The biggest misconception: that you can retrofit design controls

• [00:11:00] Forgotten elements: supplier controls and design for manufacturability

• [00:13:05] Essential elements needed before you start building

• [00:14:55] What to say to founders who claim they're too busy for planning

• [00:16:15] The value of fractional quality leadership

• [00:17:50] Hiring experienced vs inexperienced talent: when and why

• [00:19:50] Key skills that make someone successful in startup quality roles

• [00:21:35] Building and developing quality teams

• [00:23:00] Crisis management: digging out of regulatory holes

• [00:25:00] The top three compliance issues requiring remediation

• [00:27:15] Advice for companies facing their first FDA 483

• [00:30:10] How regulatory issues impact exit strategy and acquisition

• [00:31:10] Rapid fire: essential advice for medtech founders

Follow Melita and Veronica:

Connect with Melita: 

LinkedIn: https://www.linkedin.com/in/melitaball

Website: https://www.mbcaconsulting.com/about-us

Connect with Veronica: 

LinkedIn: https://www.linkedin.com/in/veronica-kingston-377725b7/

Starting a medtech company without legal guidance is like performing surgery without sterilizing your instruments. Elizabeth Parsons has seen brilliant innovations die not from failed technology, but from preventable legal mistakes that founders never saw coming. As principal of Elizabeth Parsons, PLLC and an NBCA Board member, she's watched founders give away equity to fraudsters, lose their IP to co-founder disputes, face personal liability from pierced corporate veils, and spend hundreds of thousands fixing what could have been prevented with minimal investment upfront. 

In this episode, Elizabeth walks through five critical legal areas where early-stage founders consistently stumble: founder agreements, entity governance, IP ownership, fundraising compliance, and trademark protection. She shares real stories of costly mistakes, explains why legal help is not a luxury but a necessity, and reveals exactly when founders should bring attorneys into the conversation (hint: it's earlier than you think).

Timestamps:

[00:00:00] Introduction to Elizabeth Parsons and her journey from Wall Street to startups

[00:02:35] Why Elizabeth is passionate about medtech founders

[00:04:05] The biggest misconception: legal help as a luxury

[00:06:15] Overview of the five legal mistakes that can kill a business

[00:10:10] Landmine #1: Failing to document founder agreements

[00:13:45] The 30% equity fraud story

[00:15:50] Landmine #2: Not understanding entity governance and piercing the corporate veil

[00:19:15] Real story of a founder who mixed personal and business expenses

[00:22:00] Landmine #3: Unclear IP ownership and assignment

[00:25:35] Landmine #4: Fundraising without understanding securities laws

[00:30:00] The dangers of crowdfunding for medtech companies

[00:32:10] Landmine #5: Neglecting trademark protection

[00:36:00] Warning signs that indicate you need legal help

[00:39:10] The reality of being a founder who can't do everything

[00:40:25] When and how to approach legal decisions

[00:43:50] Rapid fire: essential legal advice for founders

[00:47:10] Where to find Elizabeth and her practice

Follow Melita and Elizabeth:

Connect with Melita: 

LinkedIn: https://www.linkedin.com/in/melitaball

Website: https://www.mbcaconsulting.com/about-us

Connect with Elizabeth: 

LinkedIn: https://www.linkedin.com/company/elizabeth-parsons-pllc/

Website: https://parsonsadvisory.com/

AI is transforming clinical research faster than regulations can keep up. Olivia Longacre has spent over a decade on the front lines of global clinical trials, and she's watching MedTech companies make a critical mistake: treating AI as a replacement for human intelligence rather than a tool that requires constant oversight. With over 20,000 startups now working on software as medical devices, the stakes have never been higher. 

In this episode, Olivia breaks down the most promising AI applications in clinical research, from patient recruitment to centralized monitoring, and reveals the dangerous pitfalls that founders must avoid. She shares real stories of AI hallucinations that made it to publication, explains the crucial difference between data access and data rights, and discusses why the intersection of technology and regulatory expertise isn't quite there yet. 

Timestamps:

• [00:00:00] Introduction to Olivia Longacre and AI's impact on clinical research

• [00:01:00] How AI is outpacing governance and regulatory frameworks

• [00:02:25] The shift from onsite to centralized monitoring

• [00:03:50] What centralized monitoring means for speed and cost

• [00:05:30] The most promising AI applications for small companies

• [00:07:40] Where companies get overly excited about AI

• [00:08:35] The danger of "set it and forget it" thinking

• [00:09:25] Real story of AI creating a non-existent medical term

• [00:12:15] Why human intelligence plus AI is critical

• [00:14:55] Building teams that blend technical and clinical expertise

• [00:18:15] What founders should ask when evaluating AI tools

• [00:19:10] Data privacy and the difference between access and rights

• [00:22:40] The gray area of laboratory samples and patient consent

• [00:26:20] Looking ahead: the future of clinical research

• [00:30:00] Skills clinical research professionals need to stay relevant

• [00:31:00] Rapid fire questions

Follow Melita and Olivia:

Connect with Melita: 

LinkedIn: https://www.linkedin.com/in/melitaball

Website: https://www.mbcaconsulting.com/about-us

Connect with Olivia: 

LinkedIn: https://www.linkedin.com/in/olivia-longacre/